Natera, Inc. has announced the publication of over 100 peer-reviewed studies validating its personalized and tumor-informed molecular residual disease test, Signatera. This significant milestone highlights the clinical utility and evidence-based use of Signatera in guiding cancer care.
Company Information
Company
Natera
Location
13011 Mccallen Pass
Austin, Texas, United States
About
Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives.
Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment.
Through a cfDNA technology platform approach, we've pioneered noninvasive testing in unlimited applications—each with their own potential to revolutionize care for patients.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Natera ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
AustinBiotechnologyHealth CareGeneticsHealth Diagnostics